Raydiant Oximetry Secures FDA Approval for Lumerah Investigational Device Exemption (IDE) Study
SAN RAMON, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Raydiant Oximetry, Inc., a clinical-stage medical device company that develops medical technologies to improve outcomes for mothers and babies during childbirth, announces that the United States Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) of the Lumerah™ technology for an Early Feasibility Study (EFS) of pregnant women during labor and delivery.
